Growth hormone
Increase · large
Stimulates pituitary GH release
Literature evidence
Compound library
Vivy evidence dossier
Sermorelin
Also indexed as Geref, GRF 1-29, Sermorelin acetate
T2Peptides
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life18 min
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
IGF-1
Increase · moderate
GH/IGF-1 axis activation
Literature evidence
IGFBP-3
Increase · moderate
GH-mediated binding proteins
Literature evidence
Fasting glucose
Increase · small
GH-mediated insulin resistance
Literature evidence
Keep in view
Safety discussion points
Sermorelin is a synthetic GHRH analog (GRF 1-29) approved for growth hormone deficiency testing. Short half-life (~12-14 minutes). Not FDA-approved for anti-aging.
Keep the reference close
Track Sermorelin in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.